SG11201407599SA - Oligonucleotide chelate complex-polypeptide compositions and methods - Google Patents

Oligonucleotide chelate complex-polypeptide compositions and methods

Info

Publication number
SG11201407599SA
SG11201407599SA SG11201407599SA SG11201407599SA SG11201407599SA SG 11201407599S A SG11201407599S A SG 11201407599SA SG 11201407599S A SG11201407599S A SG 11201407599SA SG 11201407599S A SG11201407599S A SG 11201407599SA SG 11201407599S A SG11201407599S A SG 11201407599SA
Authority
SG
Singapore
Prior art keywords
international
quebec
rule
montreal
applicant
Prior art date
Application number
SG11201407599SA
Inventor
Michel Bazinet
Andrew Vaillant
Original Assignee
Replicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49581470&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201407599S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Replicor Inc filed Critical Replicor Inc
Publication of SG11201407599SA publication Critical patent/SG11201407599SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 21 November 2013 (21.11.2013) WIPOIPCT (10) International Publication Number WO 2013/170386 A1 (51) International Patent Classification: A61K 47/48 { 2006.01) A61K31/7088 (2006.01) A61K31/7115 (2006.01) A61K31/712 (2006.01) A61K31/7125 (2006.01) A61K31/713 (2006.01) A61K38/17 (2006.01) A61K 38/21 (2006.01) A61P 31/14 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/CA2013/050379 17 May 2013 (17.05.2013) English (30) Priority Data: 61/648,711 61/695,035 18 May 2012 (18.05.2012) 30 August 2012 (30.08.2012) English US US (71) Applicant: REPLICOR INC. [CA/CA]; Suite D-101, 6100 Royalmount Avenue, Montreal, Quebec H4P 2R2 (CA). (72) Inventors: BAZINET, Michel; 343 Avenue Brookfield, Montreal, Quebec H3P 2A7 (CA). VAILLANT, Andrew; 74, 11th Street, Roxboro, Quebec H8Y 3E6 (CA). (74) Agent: NORTON ROSE FULBRIGHT CANADA LLP/S.E.N.C.R.L., S.R.L.; Suite 2500, place 1 Ville-Mar- ie, Montreal, Quebec H3B 1R1 (CA). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) (54) Title: OLIGONUCLEOTIDE CHELATE COMPLEX-POLYPEPTIDE COMPOSITIONS AND METHODS 00 m o i> Fig. 88 i-H (57) Abstract: It is disclosed pharmaceutical composition containing a an oligonuclelotide chelate complex and at least one poly- O peptide or pegylated polypeptide. The present disclosure also describes additional pharmaceutical compositions and methods for the CJ treatment of diseases including viral infections.
SG11201407599SA 2012-05-18 2013-05-17 Oligonucleotide chelate complex-polypeptide compositions and methods SG11201407599SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261648711P 2012-05-18 2012-05-18
US201261695035P 2012-08-30 2012-08-30
PCT/CA2013/050379 WO2013170386A1 (en) 2012-05-18 2013-05-17 Oligonucleotide chelate complex-polypeptide compositions and methods

Publications (1)

Publication Number Publication Date
SG11201407599SA true SG11201407599SA (en) 2014-12-30

Family

ID=49581470

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407599SA SG11201407599SA (en) 2012-05-18 2013-05-17 Oligonucleotide chelate complex-polypeptide compositions and methods

Country Status (34)

Country Link
US (1) US9492506B2 (en)
EP (1) EP2849798B1 (en)
JP (1) JP2015517504A (en)
KR (1) KR102068109B1 (en)
CN (1) CN104349793B (en)
AU (1) AU2013262416B2 (en)
BR (1) BR112014028654A2 (en)
CA (1) CA2873529C (en)
CL (1) CL2014003134A1 (en)
CO (1) CO7131387A2 (en)
CR (1) CR20140527A (en)
CY (1) CY1124345T1 (en)
DK (1) DK2849798T3 (en)
DO (1) DOP2014000264A (en)
EA (1) EA035967B1 (en)
EC (1) ECSP14027694A (en)
ES (1) ES2873844T3 (en)
HK (1) HK1204279A1 (en)
HR (1) HRP20210840T1 (en)
HU (1) HUE054875T2 (en)
IL (1) IL235548B (en)
LT (1) LT2849798T (en)
MX (1) MX346239B (en)
MY (1) MY168778A (en)
NZ (1) NZ703095A (en)
PH (1) PH12014502551A1 (en)
PL (1) PL2849798T3 (en)
PT (1) PT2849798T (en)
RS (1) RS62030B1 (en)
SG (1) SG11201407599SA (en)
SI (1) SI2849798T1 (en)
TW (1) TWI635864B (en)
WO (1) WO2013170386A1 (en)
ZA (1) ZA201408674B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2818550B1 (en) 2007-05-11 2016-12-28 Adynxx, Inc. Gene expression and pain
EP2846839B1 (en) 2012-05-10 2019-02-20 Adynxx, Inc. Formulations for the delivery of active ingredients
MY172785A (en) 2012-08-30 2019-12-12 Replicor Inc Methods for the treatment of hepatitis b and hepatitis d infections
DK3166615T3 (en) * 2014-07-10 2023-11-13 Replicor Inc CHELATED PHOSPHORTIOTERATED NUCLEIC ACID REPOLYMERS FOR USE IN COMBINATION WITH AN HBV POLYMERASE INHIBITOR FOR THE TREATMENT OF HEPATITIS B AND HEPATITIS D VIRUS INFECTIONS
CN106661578B (en) 2014-08-15 2020-08-04 埃迪恩克斯股份有限公司 Oligonucleotide decoys for pain treatment
US20200147124A1 (en) * 2018-11-08 2020-05-14 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2769114B2 (en) * 1993-10-29 1998-06-25 サイクローン・ファーマシューティカルズ Pharmaceutical composition for treating minimal hepatitis B infection
UA78726C2 (en) 2001-11-01 2007-04-25 Sciclone Pharmaceuticals Inc Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
EP1537208A1 (en) * 2002-09-13 2005-06-08 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides
WO2004076474A2 (en) 2003-02-26 2004-09-10 Intermune, Inc. Polyethylene glycol modified interferon compositions and methods of use thereof
MXPA06004723A (en) * 2003-10-27 2006-07-05 Vertex Pharma Combinations for hcv treatment.
WO2006042418A1 (en) 2004-10-19 2006-04-27 Replicor Inc. Antiviral oligonucleotides
WO2007022642A2 (en) * 2005-08-25 2007-03-01 Replicor Inc. Anti-inflammatory molecules and their uses
US20090215873A1 (en) * 2005-09-29 2009-08-27 Andrew Vaillant Therapeutic Molecules and their Uses
WO2007041279A2 (en) * 2005-09-29 2007-04-12 S-Cell Biosciences, Inc. Methods to treat t-cell disorders using tisf
GB0715383D0 (en) * 2007-08-08 2007-09-19 Asterion Ltd Interferon
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents
US20090238772A1 (en) 2007-12-13 2009-09-24 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of rsv infection
CA2717792A1 (en) 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
CN103221541B (en) * 2009-05-28 2017-03-01 库尔纳公司 Antiviral gene relevant disease is treated by the natural antisense transcript suppressing antiviral gene
KR20120095397A (en) * 2009-10-16 2012-08-28 글락소 그룹 리미티드 Hbv antisense inhibitors
JP5775581B2 (en) * 2010-08-20 2015-09-09 レプリコール インコーポレーティッド Oligonucleotide chelate complex
MY172785A (en) 2012-08-30 2019-12-12 Replicor Inc Methods for the treatment of hepatitis b and hepatitis d infections

Also Published As

Publication number Publication date
AU2013262416B2 (en) 2017-05-11
EA201401278A1 (en) 2015-04-30
HUE054875T2 (en) 2021-10-28
US20130309201A1 (en) 2013-11-21
DOP2014000264A (en) 2015-01-31
CA2873529C (en) 2020-08-18
CN104349793B (en) 2017-11-10
KR20150013309A (en) 2015-02-04
PL2849798T3 (en) 2021-10-18
TW201408308A (en) 2014-03-01
PH12014502551B1 (en) 2015-01-21
MX2014014021A (en) 2015-02-10
BR112014028654A2 (en) 2017-10-10
EA035967B1 (en) 2020-09-07
AU2013262416A1 (en) 2014-12-18
US9492506B2 (en) 2016-11-15
CO7131387A2 (en) 2014-12-01
EP2849798B1 (en) 2021-04-07
PH12014502551A1 (en) 2015-01-21
CL2014003134A1 (en) 2015-02-13
IL235548B (en) 2019-07-31
RS62030B1 (en) 2021-07-30
CY1124345T1 (en) 2022-07-22
HK1204279A1 (en) 2015-11-13
CR20140527A (en) 2014-12-15
NZ703095A (en) 2016-07-29
MX346239B (en) 2017-03-13
KR102068109B1 (en) 2020-01-21
ECSP14027694A (en) 2015-12-31
WO2013170386A1 (en) 2013-11-21
EP2849798A4 (en) 2016-03-09
IL235548A0 (en) 2015-01-29
PT2849798T (en) 2021-05-18
SI2849798T1 (en) 2021-08-31
ES2873844T3 (en) 2021-11-04
CA2873529A1 (en) 2013-11-21
MY168778A (en) 2018-12-04
TWI635864B (en) 2018-09-21
HRP20210840T1 (en) 2021-08-06
ZA201408674B (en) 2016-01-27
EP2849798A1 (en) 2015-03-25
DK2849798T3 (en) 2021-05-31
CN104349793A (en) 2015-02-11
JP2015517504A (en) 2015-06-22
LT2849798T (en) 2021-08-10

Similar Documents

Publication Publication Date Title
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201807912SA (en) Vaccine against rsv
SG11201407599SA (en) Oligonucleotide chelate complex-polypeptide compositions and methods
SG11201408646VA (en) Dimeric protein with triple mutations
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201408261UA (en) Syringe
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201407669QA (en) Methods for improving safety of blood-brain barrier transport
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201407261XA (en) Oligonucleotide chelate complex methods
SG11201407655TA (en) Therapeutic uses of fibroblast growth factor 21 proteins
SG11201908650PA (en) Optimized antibody compositions for treatment of ocular disorders
SG11201810371XA (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201907804QA (en) Pharmaceutical composition comprising selexipag
SG11201808106YA (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
SG11201805001UA (en) Method of treating influenza a
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201909837YA (en) Methods for treating lung disorders
SG11201404836QA (en) Long-acting coagulation factors and methods of producing same